Abstract
Objective: To investigate whether angiotensin receptor blockers protect against Alzheimer's disease and dementia or reduce the progression of both diseases. Design: Prospective cohort analysis. Setting: Administrative database of the US Veteran Affairs, 2002-6. Population: 819 491 predominantly male participants (98%) aged 65 or more with cardiovascular disease. Main outcome measures: Time to incident Alzheimer's disease or dementia in three cohorts (angiotensin receptor blockers, lisinopril, and other cardiovascular drugs, the "cardiovascular comparator") over a four year period (fiscal years 2003-6) using Cox proportional hazard models with adjustments for age, diabetes, stroke, and cardiovascular disease. Disease progression was the time to admission to a nursing home or death among participants with pre-existing Alzheimer's disease or dementia. Results: Hazard rates for incident dementia in the angiotensin receptor blocker group were 0.76 (95% confidence interval 0.69 to 0.84) compared with the cardiovascular comparator and 0.81 (0.73 to 0.90) compared with the lisinopril group. Compared with the cardiovascular comparator, angiotensin receptor blockers in patients with pre-existing Alzheimer's disease were associated with a significantly lower risk of admission to a nursing home (0.51, 0.36 to 0.72) and death (0.83, 0.71 to 0.97). Angiotensin receptor blockers exhibited a dose-response as well as additive effects in combination with angiotensin converting enzyme inhibitors. This combination compared with angiotensin converting enzyme inhibitors alone was associated with a reduced risk of incident dementia (0.54, 0.51 to 0.57) and admission to a nursing home (0.33, 0.22 to 0.49). Minor differences were shown in mean systolic and diastolic blood pressures between the groups. Similar results were observed for Alzheimer's disease. Conclusions: Angiotensin receptor blockers are associated with a significant reduction in the incidence and progression of Alzheimer's disease and dementia compared with angiotensin converting enzyme inhibitors or other cardiovascular drugs in a predominantly male population.
| Original language | English (US) |
|---|---|
| Article number | b5465 |
| Number of pages | 1 |
| Journal | BMJ (Online) |
| Volume | 340 |
| Issue number | 7738 |
| DOIs | |
| State | Published - Jan 16 2010 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Use of angiotensin receptor blockers and risk of dementia in a predominantly male population : Prospective cohort analysis. / Li, Nien Chen; Lee, Austin; Whitmer, Rachel; Kivipelto, Miia; Lawler, Elizabeth; Kazis, Lewis E.; Wolozin, Benjamin.
In: BMJ (Online), Vol. 340, No. 7738, b5465, 16.01.2010.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Use of angiotensin receptor blockers and risk of dementia in a predominantly male population
T2 - Prospective cohort analysis
AU - Li, Nien Chen
AU - Lee, Austin
AU - Whitmer, Rachel
AU - Kivipelto, Miia
AU - Lawler, Elizabeth
AU - Kazis, Lewis E.
AU - Wolozin, Benjamin
PY - 2010/1/16
Y1 - 2010/1/16
N2 - Objective: To investigate whether angiotensin receptor blockers protect against Alzheimer's disease and dementia or reduce the progression of both diseases. Design: Prospective cohort analysis. Setting: Administrative database of the US Veteran Affairs, 2002-6. Population: 819 491 predominantly male participants (98%) aged 65 or more with cardiovascular disease. Main outcome measures: Time to incident Alzheimer's disease or dementia in three cohorts (angiotensin receptor blockers, lisinopril, and other cardiovascular drugs, the "cardiovascular comparator") over a four year period (fiscal years 2003-6) using Cox proportional hazard models with adjustments for age, diabetes, stroke, and cardiovascular disease. Disease progression was the time to admission to a nursing home or death among participants with pre-existing Alzheimer's disease or dementia. Results: Hazard rates for incident dementia in the angiotensin receptor blocker group were 0.76 (95% confidence interval 0.69 to 0.84) compared with the cardiovascular comparator and 0.81 (0.73 to 0.90) compared with the lisinopril group. Compared with the cardiovascular comparator, angiotensin receptor blockers in patients with pre-existing Alzheimer's disease were associated with a significantly lower risk of admission to a nursing home (0.51, 0.36 to 0.72) and death (0.83, 0.71 to 0.97). Angiotensin receptor blockers exhibited a dose-response as well as additive effects in combination with angiotensin converting enzyme inhibitors. This combination compared with angiotensin converting enzyme inhibitors alone was associated with a reduced risk of incident dementia (0.54, 0.51 to 0.57) and admission to a nursing home (0.33, 0.22 to 0.49). Minor differences were shown in mean systolic and diastolic blood pressures between the groups. Similar results were observed for Alzheimer's disease. Conclusions: Angiotensin receptor blockers are associated with a significant reduction in the incidence and progression of Alzheimer's disease and dementia compared with angiotensin converting enzyme inhibitors or other cardiovascular drugs in a predominantly male population.
AB - Objective: To investigate whether angiotensin receptor blockers protect against Alzheimer's disease and dementia or reduce the progression of both diseases. Design: Prospective cohort analysis. Setting: Administrative database of the US Veteran Affairs, 2002-6. Population: 819 491 predominantly male participants (98%) aged 65 or more with cardiovascular disease. Main outcome measures: Time to incident Alzheimer's disease or dementia in three cohorts (angiotensin receptor blockers, lisinopril, and other cardiovascular drugs, the "cardiovascular comparator") over a four year period (fiscal years 2003-6) using Cox proportional hazard models with adjustments for age, diabetes, stroke, and cardiovascular disease. Disease progression was the time to admission to a nursing home or death among participants with pre-existing Alzheimer's disease or dementia. Results: Hazard rates for incident dementia in the angiotensin receptor blocker group were 0.76 (95% confidence interval 0.69 to 0.84) compared with the cardiovascular comparator and 0.81 (0.73 to 0.90) compared with the lisinopril group. Compared with the cardiovascular comparator, angiotensin receptor blockers in patients with pre-existing Alzheimer's disease were associated with a significantly lower risk of admission to a nursing home (0.51, 0.36 to 0.72) and death (0.83, 0.71 to 0.97). Angiotensin receptor blockers exhibited a dose-response as well as additive effects in combination with angiotensin converting enzyme inhibitors. This combination compared with angiotensin converting enzyme inhibitors alone was associated with a reduced risk of incident dementia (0.54, 0.51 to 0.57) and admission to a nursing home (0.33, 0.22 to 0.49). Minor differences were shown in mean systolic and diastolic blood pressures between the groups. Similar results were observed for Alzheimer's disease. Conclusions: Angiotensin receptor blockers are associated with a significant reduction in the incidence and progression of Alzheimer's disease and dementia compared with angiotensin converting enzyme inhibitors or other cardiovascular drugs in a predominantly male population.
UR - http://www.scopus.com/inward/record.url?scp=74949131237&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74949131237&partnerID=8YFLogxK
U2 - 10.1136/bmj.b5465
DO - 10.1136/bmj.b5465
M3 - Article
VL - 340
JO - The BMJ
JF - The BMJ
SN - 0959-8146
IS - 7738
M1 - b5465
ER -